Zullo Investment Group Inc. Raises Holdings in Eli Lilly and Company $LLY

Zullo Investment Group Inc. lifted its stake in Eli Lilly and Company (NYSE:LLY) by 5.4% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,649 shares of the company’s stock after buying an additional 85 shares during the quarter. Zullo Investment Group Inc.’s holdings in Eli Lilly and Company were worth $1,286,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. WestEnd Advisors LLC boosted its position in Eli Lilly and Company by 210.0% during the first quarter. WestEnd Advisors LLC now owns 31 shares of the company’s stock worth $26,000 after purchasing an additional 21 shares in the last quarter. Wealth Preservation Advisors LLC purchased a new position in Eli Lilly and Company during the first quarter worth approximately $27,000. Citizens National Bank Trust Department boosted its position in Eli Lilly and Company by 180.0% during the first quarter. Citizens National Bank Trust Department now owns 42 shares of the company’s stock worth $35,000 after purchasing an additional 27 shares in the last quarter. Financial Gravity Asset Management Inc. purchased a new position in Eli Lilly and Company during the first quarter worth approximately $40,000. Finally, TD Capital Management LLC boosted its position in Eli Lilly and Company by 129.2% during the first quarter. TD Capital Management LLC now owns 55 shares of the company’s stock worth $46,000 after purchasing an additional 31 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

NYSE LLY opened at $833.08 on Friday. The company has a market cap of $788.47 billion, a PE ratio of 54.45, a price-to-earnings-growth ratio of 1.19 and a beta of 0.47. The stock’s 50 day simple moving average is $742.42 and its 200-day simple moving average is $766.36. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $937.00. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, beating the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The firm had revenue of $15.56 billion during the quarter, compared to analysts’ expectations of $14.40 billion. During the same quarter last year, the firm earned $3.92 earnings per share. The business’s revenue for the quarter was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, equities research analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on LLY. Guggenheim increased their price target on Eli Lilly and Company from $875.00 to $948.00 and gave the stock a “buy” rating in a research report on Wednesday. HSBC increased their price target on Eli Lilly and Company from $700.00 to $800.00 in a research report on Wednesday, October 1st. Wall Street Zen downgraded Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a research report on Saturday, September 20th. Daiwa Capital Markets downgraded Eli Lilly and Company from an “outperform” rating to a “neutral” rating and set a $700.00 target price on the stock. in a research report on Sunday, August 17th. Finally, Deutsche Bank Aktiengesellschaft decreased their target price on Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating on the stock in a research report on Monday, August 11th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and ten have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $948.56.

Insider Transactions at Eli Lilly and Company

In related news, Director J Erik Fyrwald purchased 1,565 shares of the business’s stock in a transaction that occurred on Tuesday, August 12th. The stock was purchased at an average price of $642.33 per share, with a total value of $1,005,246.45. Following the completion of the acquisition, the director owned 74,578 shares in the company, valued at $47,903,686.74. This trade represents a 2.14% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO David A. Ricks bought 1,632 shares of the business’s stock in a transaction on Tuesday, August 12th. The shares were acquired at an average cost of $644.77 per share, with a total value of $1,052,264.64. Following the purchase, the chief executive officer owned 546,601 shares of the company’s stock, valued at $352,431,926.77. The trade was a 0.30% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last 90 days, insiders have acquired 4,514 shares of company stock valued at $2,894,841. 0.13% of the stock is currently owned by company insiders.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.